Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis-a post-hoc analysis of a randomized, controlled trial.
Katharina DörrAndreas Anselm KammerlanderFrancesco LaurieroMatthias LorenzRodrig MarculescuDietrich BeitzkePublished in: Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2023)
In patients undergoing hemodialysis, treatment with ETEL was protective against deterioration of LV longitudinal function, as evaluated through FT CMR, when compared to the control therapy of ALFA. This effect was not mediated by the change in LV mass. Trial registration URL: https://clinicaltrials.gov/ct2/show/NCT03182699 . Unique identifier: NCT03182699.
Keyphrases
- left ventricular
- patients undergoing
- end stage renal disease
- peritoneal dialysis
- chronic kidney disease
- heart failure
- computed tomography
- replacement therapy
- machine learning
- study protocol
- hypertrophic cardiomyopathy
- magnetic resonance
- aortic stenosis
- mesenchymal stem cells
- left atrial
- percutaneous coronary intervention
- cell therapy